Sarepta Therapeutics: Beaten Down, But Not Out

Sarepta Therapeutics (SRPT) stock has fallen over 90% YTD following safety concerns, patient deaths, and an FDA investigation into its gene therapy ELEVIDYS, resulting in paused shipments and a black box warning. Despite these setbacks, the company reported $513M in Q2 revenue and holds $850M in cash, leading to a valuation at book value, significantly below its historical multiples. SRPT is undertaking a major restructuring, including a 36% workforce reduction projected to save $400M annually, and is actively engaging the FDA to restore full ELEVIDYS market access, presenting a high-risk, asymmetric upside opportunity for investors willing to stomach volatility.

Analysis

Sarepta Therapeutics (SRPT) has experienced a catastrophic stock decline of over 90% year-to-date, precipitated by severe safety concerns including patient deaths, an FDA investigation, and a subsequent pause in shipments for its flagship gene therapy, ELEVIDYS. Despite this, the company's underlying financial position appears more resilient than its stock price suggests. SRPT reported preliminary Q2 revenue of $513 million, with its stable PMO franchise contributing a significant portion and projected to generate approximately $900 million annually through 2027. The company's valuation has collapsed to its book value, a level never before seen for a stock that historically traded at a 7x-10x book multiple, while it maintains a solid liquidity position with $850 million in cash and investments. In response to the crisis, management has initiated a significant restructuring, cutting 36% of its workforce to achieve over $400 million in annual savings by 2026 and refocusing its pipeline on high-conviction siRNA programs. While the path forward for ELEVIDYS is uncertain, now bearing a black box warning and awaiting FDA approval of a revised safety protocol, the market appears to be assigning minimal value to its potential recovery, the existing PMO business, and the entire future pipeline. The high short interest, at nearly 16%, adds a volatile technical element, suggesting the stock is primed for a significant move on any definitive news.

Key Decisions for Investors

• Given the extreme stock price depreciation to book value, investors with a high risk tolerance could view SRPT as an asymmetric, deep-value opportunity, betting that the market has overly penalized the company for worst-case scenarios.
• Closely monitor any communication from the FDA regarding the proposed sirolimus protocol for ELEVIDYS, as this is the most critical near-term catalyst that could unlock significant value or confirm the market's current bearish stance.
• Factor in the company's decisive cost-cutting measures and strategic pivot to its siRNA platform, which provides a potential long-term growth narrative independent of a full ELEVIDYS recovery.
• Be aware that the high short interest of nearly 16% makes the stock susceptible to a short squeeze on any positive news, but also indicates significant institutional skepticism that could continue to weigh on the price.